Whole genome sequencing in psychiatric disorders

The WGSPD consortium

Stephan J. Sanders, Benjamin M. Neale, Hailiang Huang, Donna M. Werling, Joon Yong An, Shan Dong, Goncalo Abecasis, P. Alexander Arguello, John Blangero, Michael Boehnke, Mark J. Daly, Kevin Eggan, Daniel H. Geschwind, David C. Glahn, David B. Goldstein, Raquel E. Gur, Robert E. Handsaker, Steven A. McCarroll, Roel A. Ophoff, Aarno Palotie & 8 others Carlos N. Pato, Chiara Sabatti, Matthew W. State, A. Jeremy Willsey, Steven E. Hyman, Anjene M. Addington, Thomas Lehner, Nelson B. Freimer

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

As technology advances, whole genome sequencing (WGS) is likely to supersede other genotyping technologies. The rate of this change depends on its relative cost and utility. Variants identified uniquely through WGS may reveal novel biological pathways underlying complex disorders and provide high-resolution insight into when, where, and in which cell type these pathways are affected. Alternatively, cheaper and less computationally intensive approaches may yield equivalent insights. Understanding the role of rare variants in the noncoding gene-regulating genome through pilot WGS projects will be critical to determining which of these two extremes best represents reality. With large cohorts, well-defined risk loci, and a compelling need to understand the underlying biology, psychiatric disorders have a role to play in this preliminary WGS assessment. The Whole Genome Sequencing for Psychiatric Disorders Consortium will integrate data for 18,000 individuals with psychiatric disorders, beginning with autism spectrum disorder, schizophrenia, bipolar disorder, and major depressive disorder, along with over 150,000 controls.

Original languageEnglish (US)
Pages (from-to)1661-1668
Number of pages8
JournalNature Neuroscience
Volume20
Issue number12
DOIs
StatePublished - Dec 1 2017
Externally publishedYes

Fingerprint

Psychiatry
Genome
Technology
Major Depressive Disorder
Bipolar Disorder
Schizophrenia
Costs and Cost Analysis
Genes

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Sanders, S. J., Neale, B. M., Huang, H., Werling, D. M., An, J. Y., Dong, S., ... Freimer, N. B. (2017). Whole genome sequencing in psychiatric disorders: The WGSPD consortium. Nature Neuroscience, 20(12), 1661-1668. https://doi.org/10.1038/s41593-017-0017-9

Whole genome sequencing in psychiatric disorders : The WGSPD consortium. / Sanders, Stephan J.; Neale, Benjamin M.; Huang, Hailiang; Werling, Donna M.; An, Joon Yong; Dong, Shan; Abecasis, Goncalo; Arguello, P. Alexander; Blangero, John; Boehnke, Michael; Daly, Mark J.; Eggan, Kevin; Geschwind, Daniel H.; Glahn, David C.; Goldstein, David B.; Gur, Raquel E.; Handsaker, Robert E.; McCarroll, Steven A.; Ophoff, Roel A.; Palotie, Aarno; Pato, Carlos N.; Sabatti, Chiara; State, Matthew W.; Jeremy Willsey, A.; Hyman, Steven E.; Addington, Anjene M.; Lehner, Thomas; Freimer, Nelson B.

In: Nature Neuroscience, Vol. 20, No. 12, 01.12.2017, p. 1661-1668.

Research output: Contribution to journalReview article

Sanders, SJ, Neale, BM, Huang, H, Werling, DM, An, JY, Dong, S, Abecasis, G, Arguello, PA, Blangero, J, Boehnke, M, Daly, MJ, Eggan, K, Geschwind, DH, Glahn, DC, Goldstein, DB, Gur, RE, Handsaker, RE, McCarroll, SA, Ophoff, RA, Palotie, A, Pato, CN, Sabatti, C, State, MW, Jeremy Willsey, A, Hyman, SE, Addington, AM, Lehner, T & Freimer, NB 2017, 'Whole genome sequencing in psychiatric disorders: The WGSPD consortium', Nature Neuroscience, vol. 20, no. 12, pp. 1661-1668. https://doi.org/10.1038/s41593-017-0017-9
Sanders SJ, Neale BM, Huang H, Werling DM, An JY, Dong S et al. Whole genome sequencing in psychiatric disorders: The WGSPD consortium. Nature Neuroscience. 2017 Dec 1;20(12):1661-1668. https://doi.org/10.1038/s41593-017-0017-9
Sanders, Stephan J. ; Neale, Benjamin M. ; Huang, Hailiang ; Werling, Donna M. ; An, Joon Yong ; Dong, Shan ; Abecasis, Goncalo ; Arguello, P. Alexander ; Blangero, John ; Boehnke, Michael ; Daly, Mark J. ; Eggan, Kevin ; Geschwind, Daniel H. ; Glahn, David C. ; Goldstein, David B. ; Gur, Raquel E. ; Handsaker, Robert E. ; McCarroll, Steven A. ; Ophoff, Roel A. ; Palotie, Aarno ; Pato, Carlos N. ; Sabatti, Chiara ; State, Matthew W. ; Jeremy Willsey, A. ; Hyman, Steven E. ; Addington, Anjene M. ; Lehner, Thomas ; Freimer, Nelson B. / Whole genome sequencing in psychiatric disorders : The WGSPD consortium. In: Nature Neuroscience. 2017 ; Vol. 20, No. 12. pp. 1661-1668.
@article{69c7d48f89b442fea569f77147f6ad53,
title = "Whole genome sequencing in psychiatric disorders: The WGSPD consortium",
abstract = "As technology advances, whole genome sequencing (WGS) is likely to supersede other genotyping technologies. The rate of this change depends on its relative cost and utility. Variants identified uniquely through WGS may reveal novel biological pathways underlying complex disorders and provide high-resolution insight into when, where, and in which cell type these pathways are affected. Alternatively, cheaper and less computationally intensive approaches may yield equivalent insights. Understanding the role of rare variants in the noncoding gene-regulating genome through pilot WGS projects will be critical to determining which of these two extremes best represents reality. With large cohorts, well-defined risk loci, and a compelling need to understand the underlying biology, psychiatric disorders have a role to play in this preliminary WGS assessment. The Whole Genome Sequencing for Psychiatric Disorders Consortium will integrate data for 18,000 individuals with psychiatric disorders, beginning with autism spectrum disorder, schizophrenia, bipolar disorder, and major depressive disorder, along with over 150,000 controls.",
author = "Sanders, {Stephan J.} and Neale, {Benjamin M.} and Hailiang Huang and Werling, {Donna M.} and An, {Joon Yong} and Shan Dong and Goncalo Abecasis and Arguello, {P. Alexander} and John Blangero and Michael Boehnke and Daly, {Mark J.} and Kevin Eggan and Geschwind, {Daniel H.} and Glahn, {David C.} and Goldstein, {David B.} and Gur, {Raquel E.} and Handsaker, {Robert E.} and McCarroll, {Steven A.} and Ophoff, {Roel A.} and Aarno Palotie and Pato, {Carlos N.} and Chiara Sabatti and State, {Matthew W.} and {Jeremy Willsey}, A. and Hyman, {Steven E.} and Addington, {Anjene M.} and Thomas Lehner and Freimer, {Nelson B.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41593-017-0017-9",
language = "English (US)",
volume = "20",
pages = "1661--1668",
journal = "Nature Neuroscience",
issn = "1097-6256",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Whole genome sequencing in psychiatric disorders

T2 - The WGSPD consortium

AU - Sanders, Stephan J.

AU - Neale, Benjamin M.

AU - Huang, Hailiang

AU - Werling, Donna M.

AU - An, Joon Yong

AU - Dong, Shan

AU - Abecasis, Goncalo

AU - Arguello, P. Alexander

AU - Blangero, John

AU - Boehnke, Michael

AU - Daly, Mark J.

AU - Eggan, Kevin

AU - Geschwind, Daniel H.

AU - Glahn, David C.

AU - Goldstein, David B.

AU - Gur, Raquel E.

AU - Handsaker, Robert E.

AU - McCarroll, Steven A.

AU - Ophoff, Roel A.

AU - Palotie, Aarno

AU - Pato, Carlos N.

AU - Sabatti, Chiara

AU - State, Matthew W.

AU - Jeremy Willsey, A.

AU - Hyman, Steven E.

AU - Addington, Anjene M.

AU - Lehner, Thomas

AU - Freimer, Nelson B.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - As technology advances, whole genome sequencing (WGS) is likely to supersede other genotyping technologies. The rate of this change depends on its relative cost and utility. Variants identified uniquely through WGS may reveal novel biological pathways underlying complex disorders and provide high-resolution insight into when, where, and in which cell type these pathways are affected. Alternatively, cheaper and less computationally intensive approaches may yield equivalent insights. Understanding the role of rare variants in the noncoding gene-regulating genome through pilot WGS projects will be critical to determining which of these two extremes best represents reality. With large cohorts, well-defined risk loci, and a compelling need to understand the underlying biology, psychiatric disorders have a role to play in this preliminary WGS assessment. The Whole Genome Sequencing for Psychiatric Disorders Consortium will integrate data for 18,000 individuals with psychiatric disorders, beginning with autism spectrum disorder, schizophrenia, bipolar disorder, and major depressive disorder, along with over 150,000 controls.

AB - As technology advances, whole genome sequencing (WGS) is likely to supersede other genotyping technologies. The rate of this change depends on its relative cost and utility. Variants identified uniquely through WGS may reveal novel biological pathways underlying complex disorders and provide high-resolution insight into when, where, and in which cell type these pathways are affected. Alternatively, cheaper and less computationally intensive approaches may yield equivalent insights. Understanding the role of rare variants in the noncoding gene-regulating genome through pilot WGS projects will be critical to determining which of these two extremes best represents reality. With large cohorts, well-defined risk loci, and a compelling need to understand the underlying biology, psychiatric disorders have a role to play in this preliminary WGS assessment. The Whole Genome Sequencing for Psychiatric Disorders Consortium will integrate data for 18,000 individuals with psychiatric disorders, beginning with autism spectrum disorder, schizophrenia, bipolar disorder, and major depressive disorder, along with over 150,000 controls.

UR - http://www.scopus.com/inward/record.url?scp=85035331591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035331591&partnerID=8YFLogxK

U2 - 10.1038/s41593-017-0017-9

DO - 10.1038/s41593-017-0017-9

M3 - Review article

VL - 20

SP - 1661

EP - 1668

JO - Nature Neuroscience

JF - Nature Neuroscience

SN - 1097-6256

IS - 12

ER -